Bionomics (NASDAQ:BNOX) is a clinical-stage biotechnology company that is developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious and prevalent CNS disorders with high unmet medical needs. The company is currently advancing its proprietary lead drug candidate, BNC210, an oral, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, in Phase 3 clinical trials for the chronic treatment of Post-Traumatic Stress Disorder (PTSD) and the acute treatment of Social Anxiety Disorder (SAD). Additionally, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the US and Canada) for two drug candidates in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease and other CNS conditions. The company's pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels, which are being developed for CNS conditions with high unmet medical needs.